New Phase 3 Endometrial Cancer Trial Planned for Selinexor After Talks With FDA
March 3rd 2022Topline findings from the phase 3 SIENDO trial did not appear to likely support a supplemental new drug application use of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer, prompting the creation of a new phase 3 trial to support a future submission.
Efstathiou Discusses Impact of Niraparib Combo From MAGNITUDE in mCRPC
March 2nd 2022Eleni Efstathiou, MD, PhD, spoke about how results of the phase 3 MAGNITUDE trial, which examined the combination of niraparib with abiraterone acetate and prednisone, have the ability to change the standard of care in patients with metastatic castration-resistant prostate cancer.
Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN
March 2nd 2022Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.
Analysis Uncovers Mechanisms of Resistance to BTK Inhibitors in R/R CLL
March 2nd 2022New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.
Frontline Ibrutinib Plus Rituximab Yields Promising Response Rates for Indolent MCL
March 1st 2022Phase 2 data highlighted a high complete response rate and undetectable minimal residual disease rate in patients with indolent clinical forms of mantle cell lymphoma who received ibrutinib plus rituximab.
Oncology Peer Review On-The-Go: Ofer Sharon, MD, Discusses OncoHost and PROPHETIC Trial for NSCLC
March 1st 2022Ofer Sharon, MD, spoke about the PROphet diagnostic platform for non–small cell lung cancer and the latest interim results from the prospective PROPHETIC trial in the most recent episode of CancerNetwork’s® "Oncology Peer Review On-The-Go" podcast.
Pacritinib Granted Accelerated Approval for Use in Myelofibrosis With Severe Thrombocytopenia
March 1st 2022Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.
Providing More Equitable Care in Clinical Trials: Oncologists Reflect Over Black History Month
February 28th 2022In recognition of Black History Month, key opinion leaders from the community oncology space and beyond speak to how organizations are working to diversify clinical cancer research and combat outcome disparities.
177Lu-Dotatate Yields Clinically Relevant But Non-Significant OS Benefit for Midgut NETs
February 27th 2022Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.
AE Measures Offer Insights for Endocrine Therapy Discontinuation in DCIS
February 25th 2022Assessing adverse effects with a toxicity index and patient-reported outcomes at baseline and treatment-emergent toxicities revealed insights into why postmenopausal patients with ductal carcinoma in situ discontinued endocrine therapy.
Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal Cancers
February 25th 2022Research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium highlighted the potential to detect oropharyngeal cancer recurrence using circulating tumor tissue modified viral–human papillomavirus DNA.
Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell Carcinoma
February 25th 2022A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.